Holen Sie sich die Stockscreener-App
28.06
1.72%
-0.49
Handel nachbörslich:
27.90
-0.16
-0.57%
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com India
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - TradingView
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing By Investing.com - Investing.com South Africa
Moderna gains as Arbutus/ Genevant settlement removes major financial risk - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00 at HC Wainwright - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by TD Asset Management Inc - MarketBeat
A Glimpse Into The Expert Outlook On Roivant Sciences Through 7 Analysts - Benzinga
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds - Investing.com Australia
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders - Yahoo Finance
The Bull Case For Roivant Sciences (ROIV) Could Change Following Brepocitinib’s Priority Review In Dermatomyositis - simplywall.st
Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026 - Meyka
Wolfe Research reiterates Roivant Sciences stock rating at Outperform - Investing.com Australia
Wolfe Research reiterates Roivant Sciences stock rating at Outperform By Investing.com - Investing.com India
ROIV: $2.25B settlement with Moderna resolves all LNP patent disputes and enables major share repurchase - TradingView
Roivant Sciences Ltd. (ROIV) announced that its board of directors has officially approved a stock buyback plan totaling up to 1 billion dollars. - Bitget
Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility. - Bitget
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement By Investing.com - Investing.com Australia
Roivant Subsidiaries Genevant and Arbutus Reach $2.25 Billion Settlement with Moderna Over Patent Infringement - Quiver Quantitative
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna - marketscreener.com
Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal - Stock Titan
Jefferies reiterates Roivant Sciences stock rating on pipeline progress - Investing.com Nigeria
Jefferies reiterates Roivant Sciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan. - Bitget
Roivant Sciences receives FDA priority review for dermatomyositis drug By Investing.com - Investing.com Australia
Roivant's Priovant Says FDA Accepts Application With Priority Review for Dermatomyositis Treatment - marketscreener.com
Roivant Sciences receives FDA priority review for dermatomyositis drug - Investing.com
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewswire
Roivant Sciences Ltd. $ROIV Position Lowered by Rafferty Asset Management LLC - MarketBeat
FDA to weigh first targeted therapy for debilitating dermatomyositis - Stock Titan
According to the settlement agreement, Genevant Sciences, a subsidiary of Roivant Sciences Ltd., will grant Moderna, Inc. a non-exclusive license allowing the use of its lipid nanoparticle delivery technology for applications in the field of infectious diseases. - Bitget
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):